Revlimid gets OK in Europe for some patients with MDS

06/17/2013 |

The European Medicines Agency has approved the use of Celgene's Revlimid, or lenalidomide, in some myelodysplastic syndromes patients. The approval covers the use of the drug in patients with low- or intermediate-1-risk myelodysplastic syndrome and deletion 5q chromosomal abnormalities but no other chromo­somal ab­nor­mali­ties and who have become dependent on red blood cell transfusions and are not responding to other treatments.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC